UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Understanding how a company raises capital is often as important as understanding its product, pipeline or next catalyst. This guide explains what to check before the market prices the risk into the stock.
Dilution is not just “more shares outstanding.” It is where corporate strategy, cash runway, capital markets and shareholder protection meet. For retail investors, especially in biotech and small-cap stocks, ignoring dilution often means entering a position without understanding the most practical risk: the company may need to fund survival by issuing new shares.
A capital raise can be constructive if it funds a pivotal trial, a regulatory filing, a product launch or a genuinely accretive acquisition. It can be destructive if it merely buys a few months of time on punitive terms, with deep discounts, heavy warrants or toxic convertibles.
Share dilution occurs when a company issues new shares or securities that can become shares. The result is straightforward: the total share count rises, and each existing share represents a smaller ownership percentage of the business.
Dilution percentage ≈ new shares issued ÷ total shares after the issuanceExample: a company has 10 million shares outstanding. You own 10,000 shares, equal to 0.10% of the company. If the company issues another 5 million shares, the total share count becomes 15 million. Your 10,000 shares are unchanged, but they now represent roughly 0.067% of the company. Your economic slice is smaller.
This does not automatically mean the stock should be avoided. The better question is not “is there dilution?” but “is the company raising capital on reasonable terms, and will that capital create value per share?” In biotech, for example, a raise may be required to complete a clinical trial, reach a PDUFA date or fund a commercial launch after FDA approval.
Dilution reduces existing shareholders’ ownership percentage. It destroys value when capital is raised on poor terms or deployed badly. It can be tolerable, and sometimes useful, if it funds a milestone that increases enterprise value more than the dilution reduces ownership.
Primary dilution happens when the company issues new shares and receives the proceeds. This is the typical case for an ATM, follow-on, registered direct, PIPE or conversion of convertible securities.
A secondary offering may involve existing insiders, sponsors, funds or large shareholders selling shares they already own. In that case the company may receive no new cash and the share count may not change, but the sudden supply can pressure the stock. It is not always “dilution” in the technical sense, but it can still be an important signal.
Public companies can raise capital in different ways. The structure they choose says a lot about management’s negotiating power and the market’s willingness to fund the company.
| Instrument | How it works | Typical signal | Retail risk |
|---|---|---|---|
| ATM offering | Gradual sale of new shares into the market through a sales agent. | Flexible | Continuous pressure and slow but steady share-count growth. |
| Follow-on offering | Public offering of new shares, often through a book-building process. | Institutional access | Immediate dilution, but terms are usually more transparent. |
| Registered direct | Negotiated placement with selected investors using registered securities. | Fast | Discount, possible immediate selling pressure and warrants. |
| PIPE | Private Investment in Public Equity: private placement to institutions or accredited investors. | Urgent capital need | Deep discounts, warrants, resale registration and overhang. |
| Convertible notes / preferred | Debt or preferred stock convertible into common shares. | Complex structure | Future dilution can be hard to estimate, especially with variable conversion pricing. |
| Reverse split | Consolidation of existing shares, for example 1 new share for 10 old shares. | Defensive | Not dilutive by itself, but often followed by new issuance. |
An ATM, or At-the-Market offering, allows a company to sell newly issued shares directly into the market at prevailing prices. It is often built on a Form S-3 shelf registration and a prospectus supplement authorizing sales up to a maximum dollar amount.
The key feature is flexibility: the company does not need to sell everything at once. It can sell shares on high-volume days, after positive news or during strength in the stock. That is why ATMs are common in biotech and small-cap companies with meaningful cash burn.
If used well, an ATM can help avoid a large discounted placement. A company with important clinical data ahead may gradually strengthen its balance sheet without announcing a heavy PIPE. The market often tolerates an ATM when the company has liquidity, volume and a credible story.
The issue is that an ATM can become an open faucet. Every sale adds supply. If the company sells aggressively into every bounce, the stock may appear unable to move higher because each spike is being used to issue shares.
In quarterly 10-Q and annual 10-K filings, check how many shares were sold through the ATM, at what average price and how much capacity remains. In 424B5 filings or prospectus supplements, search for “at-the-market offering,” “sales agreement,” “aggregate offering price” and “sales agent.”
PIPE stands for Private Investment in Public Equity. It is a private placement of common stock, preferred stock, warrants or convertible securities to a limited group of institutional or accredited investors. It is fast and useful when the company needs to close financing in days.
A PIPE is often priced at a discount to the market because investors demand compensation for risk, potential initial illiquidity, volatility and capital commitment. In weak small caps, the discount can be large and paired with warrants.
A PIPE should not be judged only by the amount raised. Three items matter: the share price, warrant coverage and registration rights. If investors receive deeply discounted shares plus near-free warrants, the transaction can create a heavy overhang.
A PIPE with a deep discount, 100% warrant coverage, a low exercise price and fast resale registration can put major pressure on the stock. The risk is not only immediate dilution; it is the possibility that investors monetize the deal quickly while retail shareholders absorb the new supply.
The most dangerous structures are those where the conversion price falls as the stock price falls. The lower the stock goes, the more shares are issued to convert the same dollar amount of debt or preferred stock. This can create a toxic loop: conversion, selling, price pressure, lower conversion price, more conversion.
A follow-on public offering is a public offering after an IPO. It may be primary, where the company issues new shares and receives cash, or secondary, where existing shareholders sell shares. When the price is close to market and institutional demand is strong, a follow-on can signal healthy access to capital.
A registered direct offering is faster and negotiated with selected investors, but uses securities that are registered or immediately registrable. For retail investors, it may trade like a PIPE: discount, possible warrants, selling pressure and a gap down on announcement.
The quality of a raise depends on who is buying, the price they are paying, how much runway the cash adds and whether the company is raising from a position of strength or necessity.
Many investors look only at shares outstanding. That is a mistake. The real risk often sits in the fully diluted share count: common shares plus options, warrants, RSUs, convertible preferred stock, convertible debt and other instruments that can become common stock.
Common shares + options + RSUs + warrants + convertible preferred + convertible debt = potential fully diluted share countWarrants matter because they can hang over a stock for years. If the stock rises above the strike price, warrants can be exercised and create new shares. If the stock remains below the strike, they can still weigh on sentiment because the market knows a future supply block exists.
A reverse split consolidates several old shares into one new share. In a 1-for-10 reverse split, 1,000 shares become 100 shares and the theoretical price is multiplied by 10. The value of the position does not change mechanically.
The problem is not the reverse split itself. The problem is why the company is doing it. In small caps, the most common reason is to regain compliance with Nasdaq or NYSE minimum price requirements, especially the $1.00 minimum bid price requirement. Nasdaq has specific rules for minimum bid-price non-compliance and compliance periods.
Many microcaps reverse split to move the nominal price back above $1, then issue new shares through an ATM, PIPE or registered direct. The result for shareholders can be brutal: fewer shares after the split, then new dilution, then another decline, then risk of another reverse split.
Multiple reverse splits in a company’s history are one of the clearest signs of structural per-share value destruction. Do not just look at the “higher” post-split price; always review the split-adjusted chart and issuance history.
Dilution touches at least four areas: ownership, per-share value, runway and market perception.
If a company issues shares below perceived economic value, existing shareholders suffer a loss of per-share value. If it issues shares at favorable prices and deploys capital well, dilution can be offset or exceeded by value creation.
In biotech, runway is central. A company with six months of cash and a readout in twelve months is likely forced to raise. A company with twenty-four months of runway can negotiate from a stronger position. The same offering can be interpreted differently depending on whether it comes from strength or distress.
Cash runway ≈ cash available ÷ quarterly cash burnThe market does not react only to the math. It reacts to the signal. A raise after positive clinical data, with high-quality institutions and a modest discount, can be absorbed well. A late-night PIPE with warrants and a deep discount before a binary catalyst can damage confidence even if it technically extends runway.
At Merlintrader, dilution is not read as an isolated data point. It belongs in a broader framework that includes the balance sheet, catalysts, liquidity, execution and capital-structure quality.
The final question is always: is this company using the capital markets to build value, or using shareholders as a recurring survival mechanism?
Dilution should not be demonized, but it must be understood before buying. In small caps and biotech, many companies do not have sufficient revenue, burn cash and depend on the capital markets. That makes share structure a core part of the analysis, not an accounting detail.
A good investor does not look only at pipeline, headlines and catalysts. A good investor also studies shares outstanding, cash, burn, shelf capacity, ATM activity, warrants, convertibles and reverse-split history. Often the difference between a manageable trade and a dilution trap is found there.
Before entering: how much cash does the company have? How much does it burn per quarter? Does it have an active ATM or shelf? How many warrants exist? What is the fully diluted count? Has it reverse split before? Does the next catalyst arrive before or after the likely need for capital?
Join the Merlintrader Telegram channel for new catalyst updates and research as it goes live.
Join @merlintraderpub_com on Telegram